Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter…
LEXINGTON, Mass. and AMSTERDAM, Nov. 06, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing…
Delivered solid third quarter financial and operational performance, including growth versus prior year across all key financial metrics; reaffirming recently…
November 05, 2025 08:00 ET | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the…
Sales growth driven by launching region-specific products, expanding the distribution network, and strengthening domestic rental salesImproving quarter-on-quarter profitability through cost…
Resilient results in a complex global environment demonstrate the strength of the company’s financial model and the confidence in its…
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…
October 31, 2025 16:30 ET | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…
October 31, 2025 16:33 ET | Source: AMSC AYER, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AMSC® (NASDAQ: AMSC), a…
CHONGQING, China, Oct. 31, 2025 /PRNewswire/ -- On October 30, SERES released its financial results for the third quarter of 2025.…